Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study

被引：0
|
作者：
Cortot, A. [1 ]
Escande, F. [1 ]
Gervais, R. [2 ]
Greillier, L. [3 ]
Corre, R. [4 ]
Veillon, R. [5 ]
Ionescu, M. [6 ]
Felicio, H. [6 ]
Pau, D. [6 ]
Gregoire, V. [1 ]
Girard, N. [7 ]
机构：
[1] Univ Lille, CHU Lille, Inst Pasteur Lille, Cnrs,Inserm,Umr9020,Umr S 1277,Canther, Lille, France
[2] Ctr Francois Baclesse, Caen, France
[3] Aix Marseille Univ, Marseille, France
[4] Ch Cornouaille, Quimper, France
[5] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[6] Labs Roche, Boulogne, France
[7] Inst Curie, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
non-small cell lung cancer; ALK; Alectinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.06
引用
收藏
页码：S658 / S658
页数：1
相关论文
共 50 条
  • [41] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
    Yang, James Chih-Hsin
    Liu, Geoffrey
    Lu, Shun
    He, Jianxing
    Burotto, Mauricio
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Liu, Xiaoqing
    Zhao, Yanqiu
    Vincent, Sylvie
    Yin, Jiani
    Ma, Xin
    Lin, Huamao M.
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
  • [42] Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
    Myall, Nathaniel J.
    Lei, Amy Q.
    Wakelee, Heather A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 487 - 495
  • [43] Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
    Ou, Sai-Hong Ignatius
    Azada, Michele
    Hsiang, David J.
    Herman, June M.
    Kain, Tatiana S.
    Siwak-Tapp, Christina
    Casey, Cameron
    He, Jie
    Ali, Siraj M.
    Klempner, Samuel J.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 549 - 553
  • [44] Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review
    Zhang, Bo
    Zhang, Yanwei
    Xu, Jianlin
    Zhang, Xueyan
    Chu, Tianqing
    Wang, Shuyuan
    Qian, Jie
    Qiao, Rong
    Lu, Jun
    Zhang, Lele
    Han, Baohui
    TARGETED ONCOLOGY, 2018, 13 (05) : 631 - 639
  • [45] Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
    Crino, Lucio
    Ahn, Myung-Ju
    De Marinis, Filippo
    Groen, Harry J. M.
    Wakelee, Heather
    Hida, Toyoaki
    Mok, Tony
    Spigel, David
    Felip, Enriqueta
    Nishio, Makoto
    Scagliotti, Giorgio
    Branle, Fabrice
    Emeremni, Chetachi
    Quadrigli, Massimiliano
    Zhang, Jie
    Shaw, Alice T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2866 - +
  • [46] Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review
    Bo Zhang
    Yanwei Zhang
    Jianlin Xu
    Xueyan Zhang
    Tianqing Chu
    Shuyuan Wang
    Jie Qian
    Rong Qiao
    Jun Lu
    Lele Zhang
    Baohui Han
    Targeted Oncology, 2018, 13 : 631 - 639
  • [47] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
    Kim, D. -W.
    Ahn, M. -J
    Shi, Y.
    De Pas, T. M.
    Yang, P. -C
    Riely, G. J.
    Crino, L.
    Evans, T. L.
    Liu, X.
    Han, J. -Y.
    Salgia, R.
    Lanzalone, S.
    Polli, A.
    Iyer, S.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
  • [48] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [50] Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
    Gobbini, E.
    Chiari, R.
    Pizzutillo, P.
    Bordi, P.
    Ghilardi, L.
    Pilotto, S.
    Osman, G.
    Cappuzzo, F.
    Cecere, F.
    Riccardi, F.
    Scotti, V
    Martelli, O.
    Borra, G.
    Maiello, E.
    Rossi, A.
    Graziano, P.
    Gregorc, V
    Casartelli, C.
    Sergi, C.
    Del Conte, A.
    Delmonte, A.
    Bareggi, C.
    Cortinovis, D.
    Rizzo, P.
    Tabbo, F.
    Rossi, G.
    Bria, E.
    Galetta, D.
    Tiseo, M.
    Di Maio, M.
    Novello, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 294 - 301
12345